retatrutide efficacy clinical trials Weight loss of selected AOMs in studies Today, we shared new data

Ozempic treats type 2 diabetes but may be prescribed off-label for weight loss, if appropriate

The Tolerability Surprise Conventional wisdom would predict that a triple agonist should be significantly harder to tolerate than a dual agonist

Patients who stay at starter doses due to side effects or provider decisions will see results, but the timeline to 50 pounds stretches considerably

The study found GLP-1 (7-36) to be more potent than GIP in stimulating the release of insulin

Many women also report menstrual irregularities after starting GLP-1 treatment, a side effect that has been observed in recent studies exploring hormonal changes linked to GLP-1 medications

It crushes appetite